LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2025, outlining a year marked by leadership changes, clinical progress and strategic expansion. The company advanced development of its lead compound LB-100, expanded clinical trials with additional sites and increased enrollment, completed the acquisition of Liora Technologies Europe Ltd. to enhance its cancer treatment platform, and raised more than $11 million to strengthen its balance sheet, as it positions for continued growth and innovation in oncology.
To view the full press release, visit https://ibn.fm/LP6QH
Questions around this news
What information does a Form 10-K provide?
A Form 10-K is a public company’s annual filing with U.S. securities regulators. It typically covers the business, operations, risk factors, financial condition and results, as well as management’s discussion of the company’s performance. Investors and other readers use it to review a company’s disclosures in a standardized format.
What did LIXTE report about its progress during 2025?
The company said it moved forward with development of its lead compound, added trial locations and enrolled more participants in its clinical studies. It also reported acquiring Liora Technologies Europe Ltd. and raising more than $11 million. The release presents these developments as part of a year involving leadership changes and strategic expansion.
What is a PP2A inhibitor?
PP2A is a protein phosphatase, an enzyme involved in regulating cell activity by removing phosphate groups from proteins. An inhibitor is a substance that reduces or blocks a target’s activity. In cancer research, investigators study whether affecting this enzyme can alter processes relevant to tumor growth or treatment response.
How does proton therapy treat tumors?
Proton therapy is a form of radiation treatment that uses energized protons to damage cancer cells. Because protons can be directed to release much of their energy at a selected depth, clinicians may use the technique to limit radiation exposure to some surrounding tissues. Its suitability depends on the tumor and the patient’s circumstances.
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information can be found at www.lixte.com.
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
LIXTE Biotechnology Holdings says it filed its Form 10-K for the year ended December 31, 2025. The company describes the year as including leadership changes, progress on clinical development and strategic expansion. Its stated highlights include advancing LB-100, adding clinical trial sites and increasing enrollment, acquiring Liora Technologies Europe Ltd., and raising more than $11 million. LIXTE says LB-100 is being studied in clinical trials for ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma. Through Liora, the company is developing electronically controlled proton therapy systems, including the LiGHT System. The release identifies LIXTE as a clinical-stage pharmaceutical and med-tech company focused on cancer drug development and therapies.
Key takeaways
- LIXTE filed its annual report for the year ended December 31, 2025.
- The company says it advanced LB-100 development, added clinical trial sites and increased enrollment.
- LIXTE completed its acquisition of Liora Technologies Europe Ltd.
- The company reports raising more than $11 million.
Earlier from LIXTE Biotechnology Holdings, Inc.
- LIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
- LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials
- Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership
- Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (NASDAQ: LIXT) Saw It Coming
- LIXTE Biotechnology (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
